Loading organizations...
§ Venture Capital · WA, USA
Corporate venture capital investing in early-stage healthcare & life sciences for J&J strategic objectives.
Johnson & Johnson Innovation (JJDC) is the corporate venture capital and innovation arm of Johnson & Johnson, based in New Brunswick, New Jersey, investing in and partnering with early-stage healthcare and life sciences companies globally. The organization identifies, evaluates, and funds promising startups and technologies that align with the strategic objectives of its parent, Johnson & Johnson, across innovative medicine and medical devices. As the longest continuously running corporate venture capital firm, JJDC has been a significant player in the healthcare investment landscape for over 50 years, recently preparing to celebrate its half-century milestone. It strategically supports external innovations relevant to its parent company's core business areas, seeking to advance global health solutions and bring new therapies and technologies to market. This strategic investment vehicle was founded in 1973, building upon the legacy of Johnson & Johnson's original founders, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson.
Key people at Johnson & Johnson Innovation.
Key people at Johnson & Johnson Innovation.
Johnson & Johnson Innovation is the strategic innovation arm of Johnson & Johnson focused on accelerating healthcare breakthroughs by collaborating with entrepreneurs, startups, research institutes, and academics worldwide. Its mission is to positively impact human health by supporting the development of transformative healthcare solutions that improve lives globally. The organization operates innovation centers and incubators, such as JLABS, which provide startups with access to resources, mentorship, industry connections, and capital-efficient environments while allowing them to retain intellectual property. Johnson & Johnson Innovation spans multiple sectors including pharmaceuticals, medical devices, and biotechnology, with a focus on areas like oncology, immunology, neuroscience, cardiovascular, orthopaedics, surgery, and vision. It plays a critical role in the startup ecosystem by fostering open innovation, enabling early-stage companies to translate scientific discoveries into breakthrough therapies and technologies[1][6][7][8][9][10].
Johnson & Johnson Innovation originated as part of the broader Johnson & Johnson company, which was founded in 1886 and has evolved into a global healthcare leader. The innovation division emerged to formalize and expand the company’s efforts in partnering with external innovators and accelerating early-stage healthcare ventures. Key figures include innovation partnering directors and scientific experts who evaluate and support collaborations worldwide. The division has grown to include a global network of innovation centers and incubators, such as JLABS, which was designed to catalyze growth for emerging companies by providing a no-strings-attached model that encourages entrepreneurial freedom and intellectual property retention. This evolution reflects Johnson & Johnson’s commitment to open innovation and its strategic focus on leveraging external innovation ecosystems, including strong presences in innovation hubs like Paris and other global regions[6][7][10].
Johnson & Johnson Innovation rides the trend of open innovation and collaborative R&D in healthcare, which is increasingly vital due to the complexity and cost of developing new therapies and medical technologies. The timing is critical as advances in biology, data science, and precision medicine demand agile partnerships between large corporations and nimble startups. Market forces such as rising global healthcare needs, aging populations, and unmet medical challenges in diseases like cancer, neuropsychiatric disorders, and rare diseases create strong demand for innovation. Johnson & Johnson Innovation influences the ecosystem by bridging the gap between early scientific discovery and commercial healthcare solutions, fostering a vibrant environment where new ideas can rapidly translate into patient-impacting products[1][2][3][6].
Looking ahead, Johnson & Johnson Innovation is poised to deepen its role as a catalyst for healthcare innovation by expanding its global innovation centers and enhancing support for emerging technologies such as AI-driven drug discovery, personalized medicine, and digital health solutions. Trends like the increasing importance of biologics, multi-modality therapies, and remote patient monitoring will shape its portfolio and partnerships. Its influence is likely to grow as it continues to integrate external innovation with Johnson & Johnson’s internal R&D capabilities, accelerating the delivery of next-generation treatments to patients worldwide. This ongoing commitment ties back to its core mission of transforming lives through science-driven innovation and collaboration[1][5][6][7].
Johnson & Johnson Innovation has more than 26 tracked investments across 26 companies. The latest tracked deal is $40.0M Other Equity in Mestag Therapeutics in March 2026.
